Apyx Medical Corp(APYX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,577 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
APYX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Apyx Medical Corp (APYX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores APYX at 27.6/100 on a 32-signal composite quality model, placing it at rank #2,577 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (7.2) and revenue scale (10.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Apyx Medical Corp reports quarterly revenue of $13.9M, net income of $-3.2M, free cash flow of $-3.6M. Top institutional holders of APYX by reported 13-F value include ROYCE & ASSOCIATES, Nantahala Capital Management, Archon Capital Management, based on the most recent SEC filings. APYX trades on the Nasdaq exchange and files with the SEC under CIK 719135. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APYX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Apyx Medical Corp directly from SEC EDGAR. Apyx Medical Corp's 13F Pro composite quality score has ranged between 15 and 29 since 2021, currently 27.6 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$13.9M
Net Income
Q2 2026
$-3.2M
Free Cash Flow
Q2 2026
$-3.6M
ROIC
Q2 2026
-15.0%
D/E Ratio
Q2 2026
3.52
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+9.9% YoYNet Income
+52.2% YoYOperating Income
+65.8% YoYEPS (Diluted)
Total Assets
+3.1% YoYTotal Debt
+0.0% YoYOp. Cash Flow
+55.7% YoYFree Cash Flow
+51.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $52.8M +9.9% | $48.1M -8.1% | $52.3M +17.6% | $44.5M -8.3% | $48.5M +75.1% | $27.7M |
| Net Income | $-11.2M +52.2% | $-23.5M -25.4% | $-18.7M +19.3% | $-23.2M -52.8% | $-15.2M -27.5% | $-11.9M |
| Operating Income | $-6.4M +65.8% | $-18.8M -9.2% | $-17.3M +26.8% | $-23.6M -63.1% | $-14.4M +28.1% | $-20.1M |
| EPS (Diluted) | — | — | $-0.54 +19.4% | $-0.67 -52.3% | $-0.44 -25.7% | $-0.35 |
| Total Assets | $66.8M +3.1% | $64.8M -18.2% | $79.2M +53.0% | $51.8M -24.7% | $68.7M -7.3% | $74.1M |
| Total Debt | $37.5M +0.0% | $37.5M +13.0% | $33.2M | $0.00 | — | — |
| Operating Cash Flow | $-8.0M +55.7% | $-18.0M -243.8% | $-5.2M +74.1% | $-20.3M -94.1% | $-10.4M +35.0% | $-16.1M |
| Free Cash Flow | $-9.1M +51.4% | $-18.8M -224.6% | $-5.8M +72.8% | $-21.3M -90.6% | $-11.2M +32.9% | $-16.6M |
Get alerted when APYX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Apyx Medical Corp including:
Top Institutional Holders of APYX
ROYCE & ASSOCIATES LP
$14.7M3,274,064 shNantahala Capital Management, LLC
$14.7M3,270,248 shArchon Capital Management LLC
$11.9M2,644,717 shVANGUARD CAPITAL MANAGEMENT LLC
$6.9M1,534,847 shESSEX INVESTMENT MANAGEMENT CO LLC
$5.1M1,136,630 shAIGH Capital Management LLC
$5.1M1,128,343 shSilverberg Bernstein Capital Management LLC
$4.7M1,039,641 shCOMMONWEALTH EQUITY SERVICES, LLC
$2.9M649,061 shHORIZON KINETICS ASSET MANAGEMENT LLC
$2.6M585,000 shBlackRock, Inc.
$2.5M560,986 sh
| Fund | Value | Shares |
|---|---|---|
| ROYCE & ASSOCIATES LP | $14.7M | 3,274,064 |
| Nantahala Capital Management, LLC | $14.7M | 3,270,248 |
| Archon Capital Management LLC | $11.9M | 2,644,717 |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.9M | 1,534,847 |
| ESSEX INVESTMENT MANAGEMENT CO LLC | $5.1M | 1,136,630 |
| AIGH Capital Management LLC | $5.1M | 1,128,343 |
| Silverberg Bernstein Capital Management LLC | $4.7M | 1,039,641 |
| COMMONWEALTH EQUITY SERVICES, LLC | $2.9M | 649,061 |
| HORIZON KINETICS ASSET MANAGEMENT LLC | $2.6M | 585,000 |
| BlackRock, Inc. | $2.5M | 560,986 |
Companies Similar to APYX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
BIODESIX INC
ORTHOPEDIATRICS CORP
Stereotaxis, Inc.
NeuroPace Inc
ESTABLISHMENT LABS HOLDINGS INC.
TriSalus Life Sciences, Inc.
EXAGEN INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put APYX on your watchlist
Track score changes the day Apyx Medical Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is APYX a good stock to buy?
13F Pro's AI-powered analysis of Apyx Medical Corp (APYX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for APYX are available on the APYX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. APYX is classified as a small company.
Which hedge funds own APYX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling APYX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Apyx Medical Corp's investment landscape.